Occam Places Dan Kemp as CEO of Shinobi Therapeutics
Shinobi Therapeutics, a newly formed iPS cell therapy company created through the merger of Thyas Ltd (Japan) and Evade Biotechnology (USA) has appointed Dan Kemp as CEO. Founded on the basis of highly innovative iPSC and immune evasion research out of the University of Kyoto and UCSF, the enterprise was funded by key investors including F-Prime Capital and Eight Roads.
Previously, Dan served as CEO of Wugen Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic, off-the-shelf cell therapies. Prior to Wugen, Dan held a variety of senior Business Development and R&D leadership roles with Takeda and Novartis.
Dan received his BSc and Ph.D. in molecular pharmacology from the University of Kent (UK).
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.